

Ryan Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/624658/publications.pdf>

Version: 2024-02-01

25
papers

1,317
citations

516710

16
h-index

713466

21
g-index

26
all docs

26
docs citations

26
times ranked

2372
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. <i>Nature Communications</i> , 2021, 12, 1281.	12.8	34
2	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. <i>Nature Communications</i> , 2021, 12, 5764.	12.8	38
3	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	3.7	39
4	Obesity and Breast Cancer: A Case of Inflamed Adipose Tissue. <i>Cancers</i> , 2020, 12, 1686.	3.7	50
5	Cancer cell-intrinsic function of CD177 in attenuating β -catenin signaling. <i>Oncogene</i> , 2020, 39, 2877-2889.	5.9	11
6	IL-1 Signaling in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 1-23.	1.6	60
7	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , 2019, 11, 718.	3.7	9
8	Obesity-associated inflammation promotes angiogenesis and breast cancer via angiotensin-like 4. <i>Oncogene</i> , 2019, 38, 2351-2363.	5.9	83
9	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	4.2	42
10	Re-Evaluating E-Cadherin and β -Catenin. <i>American Journal of Pathology</i> , 2018, 188, 1910-1920.	3.8	20
11	Abstract 5529: CD177 suppresses breast cancer progression by regulating the canonical WNT β -Catenin pathway. , 2017, , .		0
12	ROR1 is an Intriguing Target for Cancer Therapy. <i>Molecular Enzymology and Drug Targets</i> , 2016, 02, .	0.1	2
13	Involvement of the NLRC4-Inflammasome in Diabetic Nephropathy. <i>PLoS ONE</i> , 2016, 11, e0164135.	2.5	42
14	Obesity and cancer: inflammation bridges the two. <i>Current Opinion in Pharmacology</i> , 2016, 29, 77-89.	3.5	266
15	Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. <i>Nature Communications</i> , 2016, 7, 13007.	12.8	186
16	Abstract B20: Obesity-induced Nlr4 inflammasome promotes angiogenesis in breast cancer. , 2016, , .		0
17	Characterization of a novel mouse model with genetic deletion of CD177. <i>Protein and Cell</i> , 2015, 6, 117-126.	11.0	36
18	Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells. <i>Cancer Research</i> , 2015, 75, 1972-1982.	0.9	53

#	ARTICLE	IF	CITATIONS
19	Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer. Genomics Data, 2015, 4, 119-122.	1.3	4
20	Abstract 3173: The NLRC4 inflammasome promotes breast cancer progression in diet-induced obese mice. , 2015, , .		0
21	Inflammasomes in cancer: a double-edged sword. Protein and Cell, 2014, 5, 12-20.	11.0	221
22	Abstract 2470: Cd177, a novel metastasis suppressor of breast cancer. , 2014, , .		0
23	Abstract 2083: WNT5a/ROR1 axis in triple-negative breast cancer progression and potential therapy. Cancer Research, 2014, 74, 2083-2083.	0.9	2
24	Beneficial and Detrimental Roles of NLRs in Carcinogenesis. Frontiers in Immunology, 2013, 4, 370.	4.8	53
25	Differential Expression of CXCL12 and CXCR4 During Human Fetal Neural Progenitor Cell Differentiation. Journal of NeuroImmune Pharmacology, 2007, 2, 251-258.	4.1	62